Clinical Trial Update: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating aibrutinib combination therapy in selected gastrointestinal and genitourinary tumors has completed with results posted. Primary disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Gastric Adenocarcinoma
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-10-26